title: Clinical impact of cycling the administration of antibiotics for febrile neutropenia in Japanese patients with hematological malignancy.
abstract: Despite the availability of newer classes of antibiotics, infection with multi-drug-resistant bacteria is a serious problem. To suppress the appearance of multi-drug-resistant bacteria and to avoid severe infection derived from febrile neutropenia (FN), we conducted cycling the administration of antibiotics for FN in patients with hematological malignancy. The treatment protocol consisted of the administration of four antibiotics each for 3 months in 1 year. The above regimen was repeated for 4 years. A total of 193 patients were registered in the protocol. The mean duration of the administration of cycling antibiotics was 5.9 days (range: 1-16 days). The frequency of FN before the study and during the study was unchanged until the third year, but decreased significantly in the fourth year. The frequency of detection of multi-drug-resistant bacteria in the first year was the same as that before the study was started, but dramatically decreased after the second year. Bacteriological treatment success rates were similar in each trimester and each year. The effective rate was not statistically different in each trimester and each year. We conclude that cycling the administration of antibiotics in patients with FN is useful for suppressing the appearance of multi-drug-resistant bacteria and for obtaining excellent clinical efficacy.
authors: Department of Gastroenterology and Hematology, Hokkaido University Graduate School of Medicine, Kita-15 Nishi-7, Kita-ku, Sapporo 060-8638, Japan. shashino@med.hokudai.ac.jp
authors: S
authors: S
authors: Hashino
authors: L
authors: L
authors: Morita
authors: H
authors: H
authors: Kanamori
authors: M
authors: M
authors: Takahata
authors: M
authors: M
authors: Onozawa
authors: M
authors: M
authors: Nakagawa
authors: T
authors: T
authors: Kawamura
authors: F
authors: F
authors: Fujisawa
authors: K
authors: K
authors: Kahata
authors: K
authors: K
authors: Izumiyama
authors: M
authors: M
authors: Yonezumi
authors: K
authors: K
authors: Chiba
authors: T
authors: T
authors: Kondo
authors: M
authors: M
authors: Asaka
references: Eur J Cancer. 1992;28A(4-5):873-8
references: 1524913
references: Clin Infect Dis. 2002 Mar 15;34(6):730-51
references: 11850858
references: Clin Infect Dis. 2002 Dec 15;35(12):1463-8
references: 12471564
references: Clin Infect Dis. 1997 Sep;25(3):551-73
references: 9314442
references: Int J Hematol. 1998 Oct;68 Suppl 1:S9-11
references: 9838737
references: Jpn J Antibiot. 2005 Aug;58(4):382-7
references: 16276739
references: Crit Care Med. 2001 Jun;29(6):1101-8
references: 11395583
references: J Antimicrob Chemother. 2006 Feb;57(2):176-89
references: 16344285
references: Arch Intern Med. 1985 Sep;145(9):1621-9
references: 3927867
references: Int J Hematol. 1999 Dec;70(4):261-7
references: 10643152
references: Clin Infect Dis. 2001 Feb 1;32(3):381-90
references: 11170945
references: Curr Opin Hematol. 2009 Jan;16(1):48-52
references: 19057204
references: Infection. 2000 Sep;28(5):278-81
references: 11073133
references: Clin Infect Dis. 2006 Aug 15;43(4):447-59
references: 16838234
references: Ann Intern Med. 2005 Jun 21;142(12 Pt 1):979-95
references: 15968013
references: Clin Infect Dis. 2004 Jul 15;39 Suppl 1:S15-24
references: 15250016
references: J Infect Dis. 1990 Mar;161(3):397-401
references: 2179421
references: Bone Marrow Transplant. 2005 Jul;36(1):59-65
references: 15908979
references: Rinsho Ketsueki. 1984 Apr;25(4):588-92
references: 6471442
references: Enferm Infecc Microbiol Clin. 2003 Feb;21(2):93-100
references: 12586033
references: Int J Infect Dis. 2011 Apr;15(4):e277-81
references: 21324723
references: J Chemother. 1998 Aug;10(4):320-5
references: 9720472